Bunzl PLC raised its revenue forecast for 2026 after reporting better-than-expected sales in the first half of the year, driven by volume growth in North America and inflation in some product categories. The company also completed the acquisition of Scientifix Group in Australia, adding about £9 million in expected revenue. Bunzl expects modest underlying growth and some inflation support for full-year revenue, with operating margins slightly down year-on-year. CEO Frank van Zanten highlighted the company's resilience and agility in delivering robust profitability and growth.
The European Commission has approved Cenrifki (tolebrutinib) by Sanofi for treating secondary progressive multiple sclerosis (SPMS) without relapses, based on positive phase 3 trial results showing it delays disability progression. This is the first ...
argenx, a global immunology company, is hosting a webinar on June 23, 2026, focused on advancing research and development of FcRn blockers for autoimmune myositis. The event features argenx's management and scientific leaders alongside key external e...
The European Commission has approved Sanofi's Cenrifki (tolebrutinib) as the first medicine targeting disability progression in secondary progressive multiple sclerosis (SPMS) without relapses. Approval is based on positive phase 3 clinical trial res...
Signify announced a new strategy at its 2026 Capital Markets Day to become a more focused and better-performing company by 2029. The plan includes prioritizing growth in connected lighting and consumer segments while optimizing less profitable areas....
Akkodis' 2026 study reveals CTO confidence in scaling AI has fallen from 82% in 2024 to 48% in 2026, despite rapid AI adoption and increased investments. The main challenge is not technology but integrating AI into company systems, processes, and dec...
